<DOC>
	<DOCNO>NCT01230658</DOCNO>
	<brief_summary>The purpose study ass anti-factor Xa concentration patient give prophylactic enoxaparin bariatric surgery .</brief_summary>
	<brief_title>Prophylactic Enoxaparin Dosing Roux-en-Y Gastric Bypass Surgery Patients St. Vincent Carmel</brief_title>
	<detailed_description>FDA-approved enoxaparin dose venous thromboembolism ( VTE ) prophylaxis fixed-dose regimen irrespective body mass index ( BMI ) actual body weight ( ABW ) . Clinical trial suggest dose may inadequate obese patient . We plan assess anti-factor-Xa concentration patient receive prophylactic enoxaparin bariatric surgery . This prospective study examine 150 anti-factor Xa concentration patient 18 year old undergoing primary Roux-en-Y gastric bypass surgery St. Vincent Carmel Bariatric Center Excellence . Patients receive vary prophylactic enoxaparin regimens surgeon 's discretion . Anti-factor-Xa concentration obtain steady state .</detailed_description>
	<criteria>Patients 18 year old undergoing primary rouxenY gastric bypass surgery St. Vincent Carmel Bariatric Center Excellence Receiving anticoagulation therapy prior surgery ( i.e . warfarin ) Did receive enoxaparin surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>prophylactic enoxaparin</keyword>
	<keyword>Roux en Y gastric bypass surgery</keyword>
</DOC>